Regeneron: Aflibercept 8 Mg Meets Primary Endpoints In Two T

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) reported that the primary endpoints were met in two trials investigating aflibercept 8 mg with 12- and 16-week dosing regimens in patients

Related Keywords

Washington , United States , , Bayer Ag , Regeneron Pharmaceuticals Inc , More Such Health News , Regeneron , Aflibercept , Meets , Primary , Endpoints , Trials , Amd ,